Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1

Virology Journal

Volumn 2, Issue , 2005, Pages

  Halford, William P ^a   Maender, Jennifer L ^b   Gebhardt, Bryan M ^c  

^a MONTANA STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RAG2 PROTEIN; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HYPOTHESIS; INNATE IMMUNITY; LEUKOCYTE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PREDICTION; PROTEIN DEPLETION; PROTEIN FUNCTION; SCID MOUSE; VIRUS PATHOGENESIS;

HUMAN HERPESVIRUS 1;

EID: 23844515846     PISSN: 1743422X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-422X-2-56     Document Type: Article

References (65)

1. Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320(26):1731-1735.
2. Dalloul A, Oksenhendler E, Chosidow O, Ribaud P, Carcelain G, Louvet S, Massip P, Lebon P, Autran B: Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J Clin Virol 2004, 30(4):329-336.
3. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T: Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996, 103(3):408-413.
4. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994, 77:525-535.
5. Rola-Pleszczynski M: In vitro induction of human cell-mediated cytotoxicity directed against herpes simplex virus-infected cells: characterization of the effector lymphocyte. J Immunol 1980, 125(4):1475-1480.
6. Bishop GA, Glorioso JC, Schwartz SA: Relationship between expression of herpes simplex virus glycoproteins and susceptibility of target cells to human natural killer activity. J Exp Med 1983, 157(5):1544-1561.
7. Fitzgerald PA, Mendelsohn M, Lopez C: Human natural killer cells limit replication of herpes simplex virus type 1 in vitro. J Immunol 1985, 134(4):2666-2672.
8. Huard B, Fruh K: A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol 2000, 30(2):509-515.
9. Ashkar AA, Rosenthal KL: Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003, 77(18):10168-10171.
10. Lopez C, Kirkpatrick D, Read SE, Fitzgerald PA, Pitt J, Pahwa S, Ching CY, Smithwick EM: Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus. J Infect Dis 1983, 147(6):1030-1035.
11. Rager-Zisman B, Quan PC, Rosner M, Moller JR, Bloom BR: Role of NK cells in protection of mice against herpes simplex virus-1 infection. J Immunol 1987, 138(3):884-888.
12. Pereira RA, Scalzo A, Simmons A: Cutting edge: A NK complexlinked locus governs acute versus latent herpes simplex virus infection of neurons. J Immunol 2001, 166(10):5869-5873.
13. Tanigawa M, Bigger JE, Kanter MY, Atherton SS: Natural killer cells prevent direct anterior-to-posterior spread of herpes simplex virus type 1 in the eye. Invest Ophthalmol Vis Sci 2000, 41(1):132-137.
14. Janeway CA, Travers P, Walport M, Schlomchik MJ: Immunobiology. 5th edition. New York, NY , Garland Science; 2001.
15. Parham P: The Immune System. 2nd edition. New York, NY ,Garland Science; 2005.
16. Biron CA: Initial and innate responses to viral infections - pattern setting in immunity or disease. Curr Opin Microbiol 1999, 2(4):374-381.
17. Whitton JL, Oldstone MBA: The immune response to viruses. In Fundamental Virology 4th edition. Edited by: Knipe DM, Howley PM. Philadelphia, PA , Lippincott, Williams, and Wilkins; 2001.
18. Orange JS: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002, 4(15):1545-1558.
19. Bukowski JF, Welsh RM: The role of natural killer cells and interferon in resistance to acute infection of mice with herpes simplex virus type 1. J Immunol 1986, 136(9):3481-3485.
20. Wu L, Morahan PS: Macrophages and other nonspecific defenses: role in modulating resistance against herpes simplex virus. Curr Top Microbiol Immunol 1992, 179:89-110.
21. Engler H, Zawatzky R, Kirchner H, Armerding D: Experimental infection of inbred mice with herpes simplex virus. IV. Comparison of interferon production and natural killer cell activity in susceptible and resistant adult mice. Arch Virol 1982, 74(4):239-247.
22. Vollstedt S, Arnold S, Schwerdel C, Franchini M, Alber G, Di Santo JP, Ackermann M, Suter M: Interplay between Alpha/Beta and Gamma Interferons with B, T, and Natural Killer Cells in the Defense against Herpes Simplex Virus Type 1. J Virol 2004, 78(8):3846-3850.
23. Hart PH, Bonder CS, Balogh J, Dickensheets HL, Donnelly RP, Finlay-Jones JJ: Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol 1999, 66(4):575-578.
24. Girard D: Phenotypic and functional change of neutrophils activated by cytokines utilizing the common cytokine receptor gamma chain. Chem Immunol Allergy 2003, 83:64-80.
25. He YW, Malek TR: The structure and function of gamma cdependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 1998, 18(6):503-524.
26. Ghiasi H, Cai S, Perng GC, Nesburn AB, Wechsler SL: The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res 2000, 45(1):33-45.
27. Slifka MK, Pagarigan RR, Whitton JL: NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol 2000, 164(4):2009-2015.
28. Halford WP, Halford KJ, Pierce AT: Mathematical analysis demonstrates that interferons-beta and -gamma interact in a multiplicative manner to disrupt herpes simplex virus replication. J Theor Biol 2005, 234:439-454.
29. Pierce AT, Desalvo J, Foster TP, Kosinski A, Weller SK, Halford WP: Interferon-beta and interferon-gamma synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells. Submitted 2005.
30. Luker GD, Prior JL, Song J, Pica CM, Leib DA: Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors. J Virol 2003, 77(20):11082-11093.
31. Halford WP, Schaffer PA: Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J Virol 2000, 74(13):5957-5967.
32. Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11:571-611.
33. Suzue K, Asai T, Takeuchi T, Koyasu S: In vivo role of IFN-gamma produced by antigen-presenting cells in early host defense against intracellular pathogens. Eur J Immunol 2003, 33(10):2666-2675.
34. Cantin E, Tanamachi B, Openshaw H: Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J Virol 1999, 73(4):3418-3423.
35. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K: Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J Virol 1999, 73(6):5196-5200.
36. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL: CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191(9):1459-1466.
37. Liu T, Khanna KM, Carriere BN, Hendricks RL: Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001, 75(22):11178-11184.
38. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O, Strupp M, Arbusow V, Brandt T: Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003, 163(6):2179-2184.
39. Aaronson DS, Horvath CM: A road map for those who don't know JAK-STAT. Science 2002, 296(5573):1653-1655.
40. Levy DE, Darnell JEJ: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3(9):651-662.
41. Hendrickson EA: The SCID mouse: relevance as an animal model system for studying human disease. Am J Pathol 1993, 143(6):1511-1522.
42. Mosier DE, Stell KL, Gulizia RJ, Torbett BE, Gilmore GL: Homozygous scid/s cid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med 1993, 177(1):191-194.
43. Nonoyama S, Smith FO, Bernstein ID, Ochs HD: Strain-dependent leakiness of mice with severe combined immune deficiency. J Immunol 1993, 150(9):3817-3824.
44. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al.: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995, 154(1):180-191.
45. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF: Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996, 26(12):2989-2998.
46. Hussell T, Openshaw PJ: Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 1998, 79(Pt 11)):2593-2601.
47. Arase H, Saito T, Phillips JH, Lanier LL: Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J Immunol 2001, 167(3):1141-1144.
48. Turk JL, Poulter LW: Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine- 125 I and 51 Cr. Int Arch Allergy Appl Immunol 1972, 43(4):620-629.
49. Stockman GD, Heim LR, South MA, Trentin JJ: Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 1973, 110(1):277-282.
50. Halford WP, Balliet JD, Gebhardt BM: Re-evaluating natural resistance to herpes simplex virus type 1. J Virol 2004, 78(18):10086-10095.
51. Ellison AR, Yang L, Voytek C, Margolis TP: Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. Virology 2000, 268(1):17-28.
52. Heyman B: Feedback regulation by IgG antibodies. Immunol Lett 2003, 88(2):157-161.
53. Ward ES, Zhou J, Ghetie V, Ober RJ: Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 2003, 15(2):187-195.
54. Kurosaka K, Watanabe N, Kobayashi Y: Potentiation by human serum of anti-inflammatory cytokine production by human macrophages in response to apoptotic cells. J Leukoc Biol 2002, 71(6):950-956.
55. Nagashunmugam T, Lubinski J, Wang L, Goldstein LT, Weeks BS, Sundaresan P, Kang EH, Dubin G, Friedman HM: In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 1998, 72(7):5351-5359.
56. Vollstedt S, Franchini M, Hefti HP, Odermatt B, O'Keeffe M, Alber G, Glanzmann B, Riesen M, Ackermann M, Suter M: Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J Exp Med 2003, 197(5):575-584.
57. Franchini M, Hefti H, Vollstedt S, Glanzmann B, Riesen M, Ackermann M, Chaplin P, Shortman K, Suter M: Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice. J Immunol 2004, 172(10):6304-6312.
58. Johnson HM, Subramaniam PS, Olsnes S, Jans DA: Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. Bioessays 2004, 26(9):993-1004.
59. Lucin P, Jonjic S, Messerle M, Polic B, Hengel H, Koszinowski UH: Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol 1994, 75(Pt 1):101-110.
60. Desloges N, Rahaus M, Wolff MH: Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol 2005, 86(Pt 1):1-6.
61. Sainz BJ, Halford WP: Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 2002, 76(22):11541-11550.
62. Sainz BJ, Lamarca HL, Garry RF, Morris CA: Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J 2005, 2(1):14.
63. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995, 375:411-415.
64. Tomazin R, van Schoot NE, Goldsmith K, Jugovic P, Sempe P, Fruh K, Johnson DC: Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 1998, 72(3):2560-2563.
65. Smith KO: Relationship between the envelope and the infectivity of herpes simplex virus. Proc Soc Exp Biol Med 1964, 115:814-816.